March 25, 2024 06:30 AM EDTUpdated 08:15 AM
Startups
Deals
Pharma

No­vo to buy mid-stage heart fail­ure biotech Car­dior for up to $1.1B

Kyle LaHucik

Senior Reporter

No­vo Nordisk plans to ac­quire Ger­man biotech Car­dior Phar­ma­ceu­ti­cals, a Phase 2 RNA start­up, for up to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times